Trials / Completed
CompletedNCT02811822
A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma
A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- GlycoMimetics Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate GMI-1271, a specific E-selectin antagonist, in multiple myeloma as adjunct to standard of care chemotherapy used to treat this disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GMI-1271 |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2019-04-01
- Completion
- 2019-04-01
- First posted
- 2016-06-23
- Last updated
- 2019-07-10
Locations
8 sites across 4 countries: Denmark, Germany, Ireland, United Kingdom
Source: ClinicalTrials.gov record NCT02811822. Inclusion in this directory is not an endorsement.